The Stepwise Approach: Low-Dose ICS Does 80–90% of the Work

A clinical brief for referring providers — part 1 of a 4-part asthma pharmacotherapy series.

Test your knowledge

At the population level, what proportion of the maximum obtainable clinical benefit of inhaled corticosteroids (ICS) is achieved at LOW doses? a) ~25% b) ~50% c) 80–90%

(Answer at the bottom — it changes how we all think about dose escalation.)

The frame

We see the same patient in every referral stream: symptoms not controlled, dose already doubled once, and the question is what to escalate next. This series walks the pharmacotherapy ladder the way the current guidelines — NAEPP 2020 (National Asthma Education and Prevention Program, JAMA 2020) and GINA 2025 (Global Initiative for Asthma) — actually order it. First: the frame.

The stepwise approach

Escalate when control is inadequate; de-escalate once control has held for ≥3 months. Severity classification sets the initial step in a treatment-naive patient; validated control scores — the Asthma Control Test (ACT) or Asthma Control Questionnaire (ACQ) — drive every decision after that. And before any step-up, four checks come first: inhaler technique, adherence, trigger avoidance, and comorbidity management (Papi et al., Lancet 2018; NAEPP 2020). In our experience, one of those four explains "uncontrolled asthma" more often than a genuinely inadequate dose does.

ICS is the cornerstone

ICS remains the most effective anti-inflammatory controller we have: it reduces eosinophilic infiltration, improves lung function, reduces symptoms and exacerbations — and halves the risk of asthma death (Papi et al., Lancet 2018).

The pearl worth taping to the wall

Low-dose ICS delivers 80–90% of the maximum obtainable benefit. Doubling the dose does NOT double the effect — the dose-response curve is flat at higher doses, while systemic effects (adrenal suppression, reduced bone mineral density, cataracts, glaucoma) are dose-dependent and climb (Beasley et al., AJRCCM 2019). The local effects — oral candidiasis, dysphonia — are the easy ones: spacer with a metered-dose inhaler, rinse the mouth after use.

One hard rule

A long-acting beta2 agonist (LABA) is never monotherapy in asthma — LABA without ICS carries a risk of severe exacerbations and death (NAEPP 2020). Every LABA your patient uses should arrive in combination with ICS.

Next in this series: the single-inhaler maintenance-and-reliever strategy (MART) — the most consequential change in the recent guidelines — and the numbers behind retiring rescue-only regimens.

The answer

c) 80–90%. Most of the ICS benefit is already on board at low dose; when a patient on low-dose ICS is still symptomatic, the higher-yield move is usually the technique/adherence/comorbidity check or a different add-on — not reflexive dose-doubling (Beasley et al., AJRCCM 2019).